-
DTC一般恶性程度低、预后好,但临床中此类患者发生骨转移的现象却并不少见,而不摄碘患者预后更差,是致死的主要原因。研究结果表明,转移灶摄碘但影像学检查持续异常患者的10年生存率为29%,而不摄碘患者的10年生存率仅为10%[1]。甲状腺乳头状癌(papillary thyroid carcinoma,PTC)骨转移患者有着较其他恶性肿瘤骨转移相对长的带瘤存活时间,因此,其早期诊治非常重要,有助于延缓并发症的发生、改善患者的生活质量及预后。对此类患者需考虑其一般状态、合并疾病和既往对治疗的反应,选择针对性的个体化治疗方案。每一例患者的病情、诉求均不同,临床诊治时需有一定的灵活性。笔者回顾性分析了一例以肱骨转移为先发症状的隐匿性PTC患者的治疗过程,依据不断更新的临床资料追根溯源,不断修正其临床诊断及治疗方案,最终患者得到了有效的治疗。现将具体情况报道如下。
以肱骨转移为先发症状的隐匿型甲状腺乳头状癌临床分析一例
Clinical analysis of a case of concealed papillary thyroid carcinoma having humeral metastasis as the first symptom
-
摘要: 以肱骨转移包块为先发症状的甲状腺乳头状癌转移病例在临床中并非罕见,笔者报道的这例病例特殊之处在于行甲状腺全切除及颈部淋巴结清扫手术后,术后病理结果未发现确切的原发病灶,再次行PET/CT检查及131I治疗后的全身碘扫描中发现了左侧髂骨病灶,行髂骨病灶手术切除术后,病理结果证实为另一处甲状腺乳头状癌骨转移灶,再次行131I治疗、规范TSH抑制治疗,诊治过程中不断更新诊断标准,制定出针对性的治疗方案,最终患者得到了有效的治疗。Abstract: A special feature of the case reported in this paper is that no definite primary lesion was found by pathology after total thyroidectomy and neck lymph-node dissection. PET/CT examination and whole-body 131I scan after radioiodine therapy revealed a left iliac bone lesion, which was resected accordingly. In addition to the pathological confirmation of another bone metastasis of papillary thyroid carcinoma, 131I therapy and regular thyroid-stimulating hormone-suppression therapy were performed again. Regarding the diagnosis and treatment process, the diagnosis was constantly updated and the targeted treatment plan was prepared. Finally, effectively treatment on the patients was achieved.
-
Key words:
-
-
[1] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8): 2892−2899. DOI: 10.1210/jc.2005-2838. [2] Schmid KW. Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands[J]. Pathologe, 2015, 36(Suppl 2): S171−S175. DOI: 10.1007/s00292-015-0071-6. [3] 熊延新, 张晓. 131I治疗分化型甲状腺癌骨转移疗效观察[J]. 吉林医学, 2008, 29(11): 904−906. DOI: 10.3969/j.issn.1004-0412.2008.11.014.
Xiong YX, Zhang X. Observation on the effects of radioactive iodine treatment in bone metastsis from differentiated thyroid cancer[J]. Jilin Med J, 2008, 29(11): 904−906. DOI: 10.3969/j.issn.1004-0412.2008.11.014.[4] Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients[J]. Thyroid, 2000, 10(3): 261−268. DOI: 10.1089/thy.2000.10.261. [5] See A, Iyer NG, Tan NC, et al. Distant metastasis as the sole initial manifestation of well-differentiated thyroid carcinoma[J]. Eur Arch Otorhinolaryngol, 2017, 274(7): 2877−2882. DOI: 10.1007/s00405-017-4532-9. [6] Xu B, Scognamiglio T, Cohen PR, et al. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon[J]. Hum Pathol, 2017, 65: 133−139. DOI: 10.1016/j.humpath.2017.05.013. [7] 许艳红, 宋红俊, 邱忠领, 等. 以骨转移为首发症状的分化型甲状腺癌的临床特征与生存分析[J]. 肿瘤, 2011, 31(6): 538−541. DOI: 10.3781/j.issn.1000-7431.2011.06.012.
Xu YH, Song HJ, Qiu ZL, et al. Differentiated thyroid carcinoma patients with bone metastasis as the initial presentation: clinical characteristics and survival analysis[J]. Tumor, 2011, 31(6): 538−541. DOI: 10.3781/j.issn.1000-7431.2011.06.012.[8] Lee J, Soh EY. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors[J]. Ann Surg, 2010, 251(1): 114−119. DOI: 10.1097/SLA.0b013e3181b7faf6. [9] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [10] Quan GMY, Pointillart V, Palussière J, et al. Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma[J]. Thyroid, 2012, 22(2): 125−130. DOI: 10.1089/thy.2010.0248. [11] 董曦文, 赵戈, 王廷. 131I联合唑来膦酸治疗甲状腺癌骨转移临床研究[J/OL]. 中国医学前沿杂志(电子版), 2015, 7(4): 102−105[2019-05-21]. http://d.wanfangdata.com.cn/periodical/zgyxqyzz201504034. DOI: 10.3969/j.issn.1674-7372.2015.04.034.
Dong XW, Zhao G, Wang T. Clinical research on 131I combined zoledronic acid in treating thyroid cancer bone metastasis[J/OL]. Chinese Journal of the Frontiers of Medical Science (Electronic Version), 2015, 7(4): 102−105[2019-05-21]. http://d.wanfangdata.com.cn/periodical/zgyxqyzz201504034. DOI: 10.3969/j.issn.1674-7372.2015.04.034.[12] 孙健雯, 宋红俊, 席闯, 等. 经皮骨水泥成形术联合131I治疗分化型甲状腺癌骨转移的疗效评价与生存分析[J]. 中华核医学与分子影像杂志, 2020, 40(6): 339−342. DOI: 10.3760/cma.j.cn321828-20200302-00082.
Sun JW, Song HJ, Xi C, et al. Efficacy evaluation of percutaneous osteoplasty combined with 131I therapy and survival analysis in patients with bone metastasis from differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2020, 40(6): 339−342. DOI: 10.3760/cma.j.cn321828-20200302-00082.[13] Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas[J]. J Clin Endocrinol Metab, 2001, 86(4): 1568−1573. DOI: 10.1210/jcem.86.4.7390. [14] Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma[J]. J Nucl Med, 1996, 37(4): 598−605. DOI: 10.1097/00004424-199604000-00009. [15] Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2018, 15(1): 37−49. DOI: 10.1677/ERC-07-0229. [16] 中国临床肿瘤学会(CSCO)甲状腺癌专家委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医师协会外科医师分会甲状腺外科医师委员会, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.
Thyroid cancer expert committee of Chinese society of Clinical Oncology (CSCO), Thyroid Disease Committee of China Research Hospital Association, Thyroid surgeons Committee of surgeons branch of Chinese Medical Doctor Association, et al. Consensus on diagnosis and management of iodine refractory differentiated thyroid cancer (2019 Edition)[J]. Chin Oncol, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.